PATENT CLAIM ANALYSIS

Application Number: 15866669
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-06
Patent Classification: ["540", "465000"]

Abstract:
The present invention relates to a theranostic system comprising a beacon and a compound selected from the group consisting of a quinazoline-based tyrosine kinase inhibitor and a natural product. The theranostic systems have use in the therapy and diagnosis of tyrosine kinase related malignancies.

Claim (Index 9):
A theranostic system according to any preceding claim, wherein the natural product is a marine-derived natural product containing one or more aromatic rings and one or more hydroxyl groups, or a phytochemical natural product selected from the group consisting of (i) chromanols of the vitamin E superfamily, and precursors, analogues and derivatives thereof; (ii) poly(oxo)phenolic compounds, and derivatives thereof; (iii) retinoids, and analogues and derivatives thereof; (iv) resveratrol, and precursors, analogues and derivatives thereof; (v) flavonoids; and (vi) terpenes and terpenoids.

Metadata:
- Claim Count in Document: 56.0
- Percentile: 86.0
- Lexical Diversity: 1.39394
- Patent Class: 540.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14751795', '10704120', '12209738', '11852604', '11807201']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6942924394188393
- 35 USC 102 Novelty (BERT): 0.591824363418274
- Combined Prediction Score: 0.6840456318187829
- Mean Citation Score: 314.902338
- Max Citation Score: 570.9696
- Similarity Product: 379.4428540969849

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test